Table 2.
Demographic and clinical characteristics and measurements at baseline of the intervention and control groups (N=168).
| Variables | Total (N=168) | Intervention group (n=84) | Control group (n=84) | t/χ2(df) or Fisher exact test |
P value |
|||
| Age (years), n (%) | 6.05 (2)a | .05 | ||||||
|
|
<45 | 52 (31) | 33 (39.3) | 19 (22.6) |
|
|
||
|
|
45-59 | 86 (51.2) | 36 (42.9) | 50 (59.5) |
|
|
||
|
|
≥60 | 30 (17.9) | 15 (17.9) | 15 (17.9) |
|
|
||
| Marital status, n (%) | 0.08 (1)a | >.99 | ||||||
|
|
Single/divorced/separated/widowed | 13 (7.7) | 6 (7.1) | 7 (8.3) |
|
|
||
|
|
Married/cohabitation | 155 (92.3) | 78 (92.9) | 77 (91.7) |
|
|
||
| Educational level, n (%) | 0.23 (1)a | .75 | ||||||
|
|
Junior high school or below | 105 (62.5) | 51 (60.7) | 54 (64.3) |
|
|
||
|
|
Senior high school or above | 63 (37.5) | 33 (39.3) | 30 (35.7) |
|
|
||
| Current employment, n (%) | 0.14 (1)a | .85 | ||||||
|
|
Employed | 38 (22.6) | 20 (23.8) | 18 (21.4) |
|
|
||
|
|
Unemployed/retired | 130 (77.4) | 64 (76.2) | 66 (78.6) |
|
|
||
| Monthly family income (USD), n (%) | 2.68 (1)a | .14 | ||||||
|
|
<1267 | 112 (66.7) | 51 (60.7) | 61 (72.6) |
|
|
||
|
|
≥1267 | 56 (33.3) | 33 (39.3) | 23 (27.4) |
|
|
||
| Payment methods of health care costs, n (%) | N/Ab | .44 | ||||||
|
|
Fully or partially covered by medical insurance | 161 (95.8) | 82 (97.6) | 79 (94) |
|
|
||
|
|
Self-paying | 7 (4.2) | 2 (2.4) | 5 (6) |
|
|
||
| Primary disease site, n (%) | 2.85c | .41 | ||||||
|
|
Cervix uteri | 65 (38.7) | 32 (38.1) | 33 (39.3) |
|
|
||
|
|
Ovary | 67 (39.9) | 37 (44) | 30 (35.7) |
|
|
||
|
|
Corpus uteri | 34 (20.2) | 15 (17.9) | 19 (33.6) |
|
|
||
|
|
Mixed typesd | 2 (1.2) | 0 (0) | 2 (2.4) |
|
|
||
| Stage of cancer, n (%) | 8.24c | .07 | ||||||
|
|
Stage I | 52 (31) | 33 (39.3) | 19 (22.6) |
|
|
||
|
|
Stage II | 38 (22.6) | 19 (22.6) | 19 (22.6) |
|
|
||
|
|
Stage III | 61 (36.3) | 24 (28.6) | 37 (44) |
|
|
||
|
|
Stage IV | 15 (8.9) | 8 (9.5) | 7 (8.3) |
|
|
||
|
|
Mixed typesd | 2 (1.2) | 0 (0) | 2 (2.4) |
|
|
||
| Treatment before chemotherapy, n (%) | 4.37c | .37 | ||||||
|
|
No | 43 (25.6) | 20 (23.8) | 23 (27.4) |
|
|
||
|
|
Surgery | 112 (66.7) | 59 (70.2) | 53 (63.1) |
|
|
||
|
|
Radiotherapy | 3 (1.8) | 1 (1.2) | 2 (2.4) |
|
|
||
|
|
Surgery + radiotherapy | 6 (3.6) | 1 (1.2) | 5 (6) |
|
|
||
|
|
Surgery + Traditional Chinese medicine treatment | 4 (2.4) | 3 (3.6) | 1 (1.2) |
|
|
||
| Cycles of chemotherapy, n (%) | 1.33c | .67 | ||||||
|
|
3 cycles or less | 25 (14.9) | 11 (13.1) | 14 (16.7) |
|
|
||
|
|
4-8 cycles | 142 (84.5) | 72 (85.7) | 70 (83.3) |
|
|
||
|
|
9 cycles or more | 1 (0.6) | 1 (1.2) | 0 (0) |
|
|
||
| Chemotherapy regimen, n (%) | 4.84c | .58 | ||||||
|
|
Paclitaxel + Cisplatin | 20 (11.9) | 7 (8.3) | 13 (15.5) |
|
|
||
|
|
Paclitaxel + Carboplatin | 109 (64.9) | 58 (69) | 51 (60.7) |
|
|
||
|
|
Bleomycin + Etoposide + Cisplatin | 8 (4.8) | 4 (4.8) | 4 (4.8) |
|
|
||
|
|
Docetaxel + Carboplatin | 17 (10.1) | 7 (8.3) | 10 (11.9) |
|
|
||
|
|
Doxorubicin + Carboplatin | 5 (3) | 2 (2.4) | 3 (3.6) |
|
|
||
|
|
Ifosfamide + Epirubicin | 4 (2.4) | 2 (2.4) | 2 (2.4) |
|
|
||
|
|
Others | 5 (3) | 4 (4.8) | 1 (1.2) |
|
|
||
| Mishel Uncertainty in Illness Scale for Adults, mean (SD) | 70.27 (12.34) | 70.88 (11.55) | 69.67 (13.13) | –0.64 (166)e | .53 | |||
| Functional Assessment of Cancer Therapy-General, mean (SD) | 67.30 (15.85) | 67.03 (14.36) | 67.58 (17.28) | 0.23 (166)e | .82 | |||
| MD Anderson Symptom Inventory, mean (SD) | 2.92 (1.68) | 2.98 (1.88) | 2.86 (1.46) | –0.44 (166)e | .66 | |||
| Multidimensional Scale of Perceived Social Support, mean (SD) | 5.44 (0.85) | 5.37 (0.78) | 5.51 (0.92) | 1.08 (166)e | .28 | |||
aChi-square test.
bN/A: not applicable. No value is provided for Fisher exact test in a 2×2 contingency table.
cFisher exact test. No degrees of freedom are used in Fisher exact test.
dMixed types (n=2): one participant was diagnosed with primary stage III ovarian cancer and primary stage I corpus uteri cancer, and the other one was diagnosed with primary stage I cervix uteri cancer and primary stage I ovarian cancer.
eIndependent 2-sided t test value.